Navigation Links
Covance Board Authorizes $300 Million Stock Buyback
Date:1/25/2012

PRINCETON, N.J., Jan. 25, 2012 /PRNewswire/ -- Covance Inc. (NYSE: CVD) said today that its Board of Directors has authorized the repurchase of up to $300 million of its outstanding common stock. This authorization is in addition to the approximately 800,000 shares remaining under a previously-announced repurchase authorization and currently represents approximately ten percent of the Company's common stock. Any purchases under this buyback would be dependent upon business and market conditions and other factors.  The stock purchases may be made from time to time and may be made through a variety of methods including open market purchases, privately negotiated transactions, block trades, and 10b5-1 plans.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $2 billion, global operations in more than 30 countries, and more than 11,000 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  These
'/>"/>

SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2011 Financial Results Conference Call
2. Covance to Present at Credit Suisse 2011 Healthcare Conference
3. Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey
4. Covance Receives Good Laboratory Practice Certification for Its Early Development Facility in Shanghai, China
5. Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2011 Financial Results Conference Call
6. Covance to Present at Morgan Stanley Global Healthcare Conference
7. Covance Reports Second Quarter Revenue of $518 Million, GAAP EPS of $0.61, and Pro Forma EPS of $0.66
8. Covance to Present at Bairds 2011 Growth Stock Conference
9. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2011 Financial Results Conference Call
10. Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference
11. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... SAN DIEGO , July 1, 2015  AVACEN, Inc. ... a second AVACEN patent covering the medical technology platform supporting ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... The apparatus and methods patent no. 9,066,781 - Methods And ... devices manufactured by AVACEN and specific methods of use, referred ...
(Date:7/1/2015)... Fla. , July 1, 2015 Rock ... development company focused on chronic inflammatory disease and neurologic ... of principle study with anatabine citrate, the Company,s lead ... oral dose of anatabine citrate can significantly inhibit the ... subjects. The Company is developing this compound in a ...
(Date:7/1/2015)... , July 1, 2015 Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... Bob Radie , president and chief executive officer, ... summer. He will provide an update on Egalet,s ... tromethamine) Nasal Spray, approved product OXAYDO ™ ...
Breaking Medicine Technology:AVACEN Medical Patent Issued 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3
... -Study Results Show Cethromycin Not Associated with QT Prolongation- ... -Favorable Cardiac Safety Profile Strengthens NDA-, CHICAGO, ... ADLS ), today announced positive results from Trial,CL07-001, a ... cethromycin. This study was conducted to evaluate the cardiac,safety ...
... landscape of scientific,publications strategy, planning and delivery is ... global publications groups are fully,located in the marketing ... groups to increase clinical presentation, according to a ... a benchmarking study that included such influential companies ...
Cached Medicine Technology:Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 2Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 3Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 4Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 5Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 6Industry Executives Finding Value in Shift of Scientific Publications 2
(Date:7/1/2015)... ... , ... For decades, researchers in the genetics field have theorized that the ... changing after development in the womb. Now, researchers from the Icahn School of Medicine ... life – a process which helps to switch genes on and off. This histone ...
(Date:7/1/2015)... York, NY (PRWEB) , ... July 01, 2015 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – today announced that they will welcome four new members to their ...
(Date:7/1/2015)... ORANGE, Calif. (PRWEB) , ... July 01, 2015 ... ... advanced orthodontic technology and services, today announced that its fifth annual Smile for ... has raised $80,000 for the non-profit organization. In addition to supporting S4L in ...
(Date:7/1/2015)... Japan (PRWEB) , ... July 01, 2015 , ... ... 2015 of a new extraction plant for Linablue®, Spirulina-derived natural blue food coloring. ... Nutritionals, LLC, the DIC Group’s U.S. Spirulina* production base, began in May 2014. ...
(Date:7/1/2015)... ... ... The Collaborative for Children and Families (CCF) announced that it received a ... to improve quality of care and save costs for the child welfare sector by ... in New York’s Medicaid system. Experts agree that children need thorough solutions to live ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3
... after markets close at 2:00 p.m. PT (5:00 p.m. ET) ... MASI ), the inventor of Pulse CO-Oximetry and Measure-Through Motion ... quarter and fiscal year 2008 financial results for the period ... March 3, 2009.A conference call to review the results will ...
... Its Roster, Fielding Five Teams to Spread Personal Messages ... 1 and Type 2 DiabetesBRIDGEWATER, N.J., Feb. 5 ... glargine [rDNA origin] injection) and rapid-acting insulin Apidra(R) (insulin ... sponsors of Team Type 1, a team of amateur ...
... Feb. 5 Palomar Medical Technologies, Inc. (Nasdaq: ... light-based systems for cosmetic treatments, today announced financial results ... 2008. Revenues for the quarter ended December 31, ... product revenues, $2.2 million were royalty revenues, $0.5 million ...
... TORONTO, Feb. 5 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ... TTHI ) today announced the completion of patient ... gastrin analogue, TT-223, in patients with type 2 ... dose-ranging study to evaluate the safety, tolerability and ...
... Health Records (EHRs) have been promoted by industry and ... controlling costs. However, actual adoption of EHRs has ... to implementation costs, security, privacy, and systems integration. ... adoption barriers pale in comparison to basic usability and ...
... and identity theft response leader Kroll Fraud Solutions will host webinars ... a team of Kroll data security experts. , ... ... theft response leader Kroll Fraud Solutions will host a ...
Cached Medicine News:Health News:Masimo to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 3, 2009 2Health News:Masimo to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 3, 2009 3Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 2Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 3Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 4Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 5Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 6Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 7Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 2Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 3Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 4Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 5Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 6Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 7Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 8Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 9Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 10Health News:Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients 2Health News:How to Select an Electronic Health Record System That Healthcare Professionals Can Use 2Health News:Kroll Fraud Solutions To Host Free Webinar Series on Preparing for and Responding to a Healthcare Data Breach 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: